Text and Data Mining valid from 2018-11-14
Received: 28 June 2018
Revised: 17 September 2018
Accepted: 12 October 2018
First Online: 14 November 2018
: L.G.: Research Fuding: Merck. Advisory Role: Merck, Genentech/Roche, Pfizer, Ignyta, Syndax, AbbVie, AstraZeneca, Bristol-Myers Squibb; L.D.: Employee of Merck KGaA; F.C.: Employee of Sanofi; D.M.H.: Research Funding: NIH R01 CA204749, AstraZeneca, Puma Biotechnology, Loxo Oncology. Consulting or Advisory Role: AstraZeneca, Atara Biotherapeutics, Chugai Pharma, CytomX Therapeutics, Boehringer Ingelheim, Pfizer, Genetech, Bayer, Debiopharm, ArQule; R.S.H.: Consulting: Boehringer Ingelheim. Research funding (to institution): Novartis, Celgene, Corvus, Genentech/Roche, Millenium, Mirati, ABBVie, Incyte, Exelixis, Daichi, Agios.
: Available through EMD Serono.
: All patients signed an informed consent prior to participation in the study. Ethical approval was given by the Institutional Review Boards at all participating institutions. The study was conducted according to the Declaration of Helsinki.
: Provided by EMD Serono.
: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).